Seaport Therapeutics, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Seaport reported Q3 2026 results with $403.8M in cash/investments (91% of total assets) expected to fund operations into 2029. Key clinical milestones: GlyphAllo Phase 1 driving trial met primary endpoint (375mg did not impair next-morning driving vs placebo); first patient dosed in GlyphAgo Phase 2a GAD trial with Phase 2/3 initiation planned 1H 2027; BUOY-1 Phase 2b MDD trial enrollment on track with topline data expected 1H 2027. Q3 R&D expenses increased $3.4M to $23.9M; net loss widened to $26.4M vs $22.5M prior year.
Why this rating
Strong cash position and clear clinical milestones are meaningful for a $417.6M asset company; multiple upcoming data readouts in 2027-2028 represent real value inflection points. Not transformational but materially de-risks near-term execution.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.